Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate

Jan K. Buitelaar, J. J. Sandra Kooij, J. Antoni Ramos-Quiroga, Joachim Dejonckheere, Miguel Casas, Joop C. van Oene, Barbara Schäuble, Goetz-Erik Trott

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: We conducted a post-hoc analysis of the Long-Acting MethylpheniDate in Adult attention-deficit hyperactivity disorder (LAMDA) study to investigate predictors of response in adults with ADHD randomly assigned to Osmotic Release Oral System (OROS)®-methylphenidate hydrochloride (MPH) 18, 36 or 72mg or placebo. Methods: LAMDA comprised a 5-week, double-blind (DB) period, followed by a 7-week, open-label (OL) period. A post-hoc analysis of covariance and a logistic regression analysis were undertaken to detect whether specific baseline parameters or overall treatment compliance during the double-blind phase contributed to response. The initial model included all covariates as independent variables; a backward stepwise selection method was used, with stay criteria of p< 0.10. Six outcomes were considered: change from baseline CAARS:O-SV (physician-rated) and CAARS:S-S (self-report) scores at DB and OL end points, and response rate (≥ 30% decrease in CAARS:O-SV score from baseline) and normalization of CAARS:O-SV score at DB end point. Results: Taking into account a significant effect of OROS®-MPH treatment versus placebo in the original analysis (p≤0.015), across the outcomes considered in this post-hoc analysis, higher baseline CAARS scores were most strongly predictive of superior outcomes. Male gender and lower academic achievement were also predictive for improved results with certain outcomes. Conclusions: Several baseline factors may help to predict better treatment outcomes in adults receiving OROS®-MPH; however, further research is required to confirm these findings and examine their neurobiological underpinnings. © 2010.
Original languageEnglish
Pages (from-to)554-560
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume35
Issue number2
DOIs
Publication statusPublished - 2011
Externally publishedYes

Cite this

Buitelaar, Jan K. ; Kooij, J. J. Sandra ; Ramos-Quiroga, J. Antoni ; Dejonckheere, Joachim ; Casas, Miguel ; van Oene, Joop C. ; Schäuble, Barbara ; Trott, Goetz-Erik. / Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2011 ; Vol. 35, No. 2. pp. 554-560.
@article{8d866a26052c498c8b6f62a2401879e6,
title = "Predictors of treatment outcome in adults with ADHD treated with OROS{\circledR} methylphenidate",
abstract = "Background: We conducted a post-hoc analysis of the Long-Acting MethylpheniDate in Adult attention-deficit hyperactivity disorder (LAMDA) study to investigate predictors of response in adults with ADHD randomly assigned to Osmotic Release Oral System (OROS){\circledR}-methylphenidate hydrochloride (MPH) 18, 36 or 72mg or placebo. Methods: LAMDA comprised a 5-week, double-blind (DB) period, followed by a 7-week, open-label (OL) period. A post-hoc analysis of covariance and a logistic regression analysis were undertaken to detect whether specific baseline parameters or overall treatment compliance during the double-blind phase contributed to response. The initial model included all covariates as independent variables; a backward stepwise selection method was used, with stay criteria of p< 0.10. Six outcomes were considered: change from baseline CAARS:O-SV (physician-rated) and CAARS:S-S (self-report) scores at DB and OL end points, and response rate (≥ 30{\%} decrease in CAARS:O-SV score from baseline) and normalization of CAARS:O-SV score at DB end point. Results: Taking into account a significant effect of OROS{\circledR}-MPH treatment versus placebo in the original analysis (p≤0.015), across the outcomes considered in this post-hoc analysis, higher baseline CAARS scores were most strongly predictive of superior outcomes. Male gender and lower academic achievement were also predictive for improved results with certain outcomes. Conclusions: Several baseline factors may help to predict better treatment outcomes in adults receiving OROS{\circledR}-MPH; however, further research is required to confirm these findings and examine their neurobiological underpinnings. {\circledC} 2010.",
author = "Buitelaar, {Jan K.} and Kooij, {J. J. Sandra} and Ramos-Quiroga, {J. Antoni} and Joachim Dejonckheere and Miguel Casas and {van Oene}, {Joop C.} and Barbara Sch{\"a}uble and Goetz-Erik Trott",
year = "2011",
doi = "10.1016/j.pnpbp.2010.12.016",
language = "English",
volume = "35",
pages = "554--560",
journal = "Progress in Neuropsychopharmacology & Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "2",

}

Buitelaar, JK, Kooij, JJS, Ramos-Quiroga, JA, Dejonckheere, J, Casas, M, van Oene, JC, Schäuble, B & Trott, G-E 2011, 'Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate' Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 2, pp. 554-560. https://doi.org/10.1016/j.pnpbp.2010.12.016

Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate. / Buitelaar, Jan K.; Kooij, J. J. Sandra; Ramos-Quiroga, J. Antoni; Dejonckheere, Joachim; Casas, Miguel; van Oene, Joop C.; Schäuble, Barbara; Trott, Goetz-Erik.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 35, No. 2, 2011, p. 554-560.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate

AU - Buitelaar, Jan K.

AU - Kooij, J. J. Sandra

AU - Ramos-Quiroga, J. Antoni

AU - Dejonckheere, Joachim

AU - Casas, Miguel

AU - van Oene, Joop C.

AU - Schäuble, Barbara

AU - Trott, Goetz-Erik

PY - 2011

Y1 - 2011

N2 - Background: We conducted a post-hoc analysis of the Long-Acting MethylpheniDate in Adult attention-deficit hyperactivity disorder (LAMDA) study to investigate predictors of response in adults with ADHD randomly assigned to Osmotic Release Oral System (OROS)®-methylphenidate hydrochloride (MPH) 18, 36 or 72mg or placebo. Methods: LAMDA comprised a 5-week, double-blind (DB) period, followed by a 7-week, open-label (OL) period. A post-hoc analysis of covariance and a logistic regression analysis were undertaken to detect whether specific baseline parameters or overall treatment compliance during the double-blind phase contributed to response. The initial model included all covariates as independent variables; a backward stepwise selection method was used, with stay criteria of p< 0.10. Six outcomes were considered: change from baseline CAARS:O-SV (physician-rated) and CAARS:S-S (self-report) scores at DB and OL end points, and response rate (≥ 30% decrease in CAARS:O-SV score from baseline) and normalization of CAARS:O-SV score at DB end point. Results: Taking into account a significant effect of OROS®-MPH treatment versus placebo in the original analysis (p≤0.015), across the outcomes considered in this post-hoc analysis, higher baseline CAARS scores were most strongly predictive of superior outcomes. Male gender and lower academic achievement were also predictive for improved results with certain outcomes. Conclusions: Several baseline factors may help to predict better treatment outcomes in adults receiving OROS®-MPH; however, further research is required to confirm these findings and examine their neurobiological underpinnings. © 2010.

AB - Background: We conducted a post-hoc analysis of the Long-Acting MethylpheniDate in Adult attention-deficit hyperactivity disorder (LAMDA) study to investigate predictors of response in adults with ADHD randomly assigned to Osmotic Release Oral System (OROS)®-methylphenidate hydrochloride (MPH) 18, 36 or 72mg or placebo. Methods: LAMDA comprised a 5-week, double-blind (DB) period, followed by a 7-week, open-label (OL) period. A post-hoc analysis of covariance and a logistic regression analysis were undertaken to detect whether specific baseline parameters or overall treatment compliance during the double-blind phase contributed to response. The initial model included all covariates as independent variables; a backward stepwise selection method was used, with stay criteria of p< 0.10. Six outcomes were considered: change from baseline CAARS:O-SV (physician-rated) and CAARS:S-S (self-report) scores at DB and OL end points, and response rate (≥ 30% decrease in CAARS:O-SV score from baseline) and normalization of CAARS:O-SV score at DB end point. Results: Taking into account a significant effect of OROS®-MPH treatment versus placebo in the original analysis (p≤0.015), across the outcomes considered in this post-hoc analysis, higher baseline CAARS scores were most strongly predictive of superior outcomes. Male gender and lower academic achievement were also predictive for improved results with certain outcomes. Conclusions: Several baseline factors may help to predict better treatment outcomes in adults receiving OROS®-MPH; however, further research is required to confirm these findings and examine their neurobiological underpinnings. © 2010.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79952901836&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/21185347

U2 - 10.1016/j.pnpbp.2010.12.016

DO - 10.1016/j.pnpbp.2010.12.016

M3 - Article

VL - 35

SP - 554

EP - 560

JO - Progress in Neuropsychopharmacology & Biological Psychiatry

JF - Progress in Neuropsychopharmacology & Biological Psychiatry

SN - 0278-5846

IS - 2

ER -